Cardiol Therapeutics (TSE:CRDL) Stock Price Down 0.7% - Here's Why

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s share price traded down 0.7% during mid-day trading on Tuesday . The company traded as low as C$1.37 and last traded at C$1.39. 25,955 shares were traded during mid-day trading, a decline of 76% from the average session volume of 107,933 shares. The stock had previously closed at C$1.40.Get Cardiol Therapeutics alerts:Cardiol Therapeutics Stock PerformanceThe company has a market cap of C$139.00 million, a PE ratio of -3.39 and a beta of 1.55. The stock's 50 day simple moving average is C$1.47 and its two-hundred day simple moving average is C$1.61. The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59. Cardiol Therapeutics (TSE:CRDL - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. As a group, research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year. Cardiol Therapeutics Company Profile (Get Free Report)Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.Featured ArticlesFive stocks we like better than Cardiol TherapeuticsThe boring AI play that could pay up to $4,290 monthlyPut $1,000 into this stock by Jan 1 [Not NVDA]Trump’s “real estate deal for America” explainedA month before the crashTrump Did WHAT??This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Cardiol Therapeutics Right Now?Before you consider Cardiol Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here